COVID-19 vaccines are of great importance in reducing SARS-CoV-2 infection and severe
cases. Patients with autoimmune inflammatory rheumatic diseases (AIIRDs) have been …

Objectives Successful vaccination is key to overcoming the COVID-19 pandemic.
Immunosuppressive medication is known to potentially compromise vaccination responses …

Background We describe the early experiences of adults with systemic rheumatic disease
who received the COVID-19 vaccine. Methods From 2 April to 30 April 2021, we conducted …

Objective To determine COVID-19 vaccine-related adverse events (AEs) in the seven-day
post-vaccination period in patients with SLE vs autoimmune rheumatic diseases (AIRDs) …

Objectives The COVID-19 vaccination in autoimmune diseases (COVAD) study aimed to
assess short-term COVID-19 vaccination-related adverse events (AEs) in RA patients …

SARS-CoV-2 vaccines reduce the risk of COVID-19. 1–3 However, some disease-modifying
anti-rheumatic drugs (DMARDs), particularly glucocorticoids, methotrexate, mycophenolate …

Introduction Emerging evidence supports the immunogenic response to mRNA COVID-19
vaccine in patients with autoimmune rheumatic diseases (ARD). However, large-scale data …

The ongoing COVID‑19 pandemic continues to be a cause of unprecedented morbidity and
mortality. Vaccination provides a ray of hope as a powerful tool for reducing the poor clinical …

We read with interest the recent report by Geisen et al, 1 who describe the immunogenicity
and safety profile of two mRNA-based anti-SARS-CoV-2 vaccines in a cohort of 26 patients …

Objective To develop guidance on the use of coronavirus disease 2019 (COVID-19)
vaccines in patients with autoimmune rheumatic diseases (ARD). Methods The Canadian …